We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New RNA Research Kits Save Time, Reduce Variability

By LabMedica International staff writers
Posted on 03 Jun 2010
Two assay kits for RNA research are among several new products recently made available to molecular biologists and genome researchers.

Two assay systems recently released for marketing by Qiagen (Hilden, Germany) focus on RNA research. More...
The first is called "FlexiTube siRNA Premix.” In this product siRNA for the gene of interest and a highly efficient transfection reagent are already premixed and provided in a single tube.

FlexiTube siRNA Premix includes a specialized buffer that increases the stability of siRNA-reagent complexes. The ratio of reagent to siRNA in FlexiTube siRNA Premix is preoptimized to provide the highest transfection efficiency and gene knockdown. FlexiTube siRNA Premix is ready-to-use for cell transfection. The user simply adds the reagents to cells and incubates. This saves a significant amount of time and labor compared to a typical transfection experiment in which siRNA is diluted, mixed with transfection reagent, and then incubated to allow siRNA-reagent complex formation prior to adding the complexes to the cells and incubating.

With FlexiTube siRNA Premix, RNAi experiments get off to a faster start, as there is no need to optimize siRNA to reagent ratio. Tedious optimization experiments involving multiple transfections are minimized or eliminated, as FlexiTube siRNA Premix provides siRNA and reagent premixed at an optimal ratio. Multiple transfections can be performed from a single FlexiTube siRNA Premix, which reduces variability, enabling consistency across experiments and more reliable results.

The second line of products for RNA research is "miScript Target Protectors.” These are innovative tools that provide valuable insights into the roles of miRNAs in regulation of individual genes. A miScript Target Protector is designed to protect the miRNA-binding site of a specific target gene. After transfection, the miScript Target Protector binds to the miRNA-binding site, blocking miRNA access to the site and preventing gene downregulation by a specific miRNA.

miScript Target Protector transfection is followed by phenotype or gene expression analysis. Increased target-gene expression, a change in signaling patterns, or an altered phenotype, can all provide evidence that the miRNA and target under study are involved in the pathway or phenotype of interest. The role of miRNAs in various pathways can be studied by examination of specific phenotypes after transfection of different miScript Target Protectors.

Information about these and other genomic research tools is easily accessed through the "GeneGlobe” portal located at Qiagen's website.

Related Links:
Qiagen



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.